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Abstract: Optical imaging of tissue autofluorescence has the potential to 
provide  rapid  label-free  screening  and  detection  of  surface  tumors  for 
clinical  applications,  including  when  combined  with  endoscopy. 
Quantitative imaging of intensity-based contrast is notoriously difficult and 
spectrally resolved imaging does not always provide sufficient contrast. We 
demonstrate that fluorescence lifetime imaging (FLIM) applied to intrinsic 
tissue  autofluorescence  can  directly  contrast  a  range  of  surface  tissue 
tumors,  including  in  gastrointestinal  tissues,  using  compact,  clinically 
deployable  instrumentation  achieving  wide-field  fluorescence  lifetime 
images  of  unprecedented  clarity.  Statistically  significant  contrast  is 
observed  between  cancerous  and  healthy  colon  tissue  for  FLIM  with 
excitation  at  355  nm.  To  illustrate  the  clinical  potential,  wide-field 
fluorescence lifetime images of unstained ex vivo tissue have been acquired 
at near video rate, which is an important step towards real-time FLIM for 
diagnostic and interoperative imaging, including for screening and image-
guided biopsy applications. 
©2010 Optical Society of America 
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1. Introduction 
Early detection of cancer allows earlier treatment and significantly improves prognosis. While 
advanced exophytic tumours can usually be visualised, the cellular and tissue perturbations of 
early  neoplasia  may not be  apparent by direct inspection under  white light and are often 
beyond  the  discrimination  of  conventional  non-invasive  diagnostic  imaging  techniques.  A 
number  of  label-free  modalities  based  on  the  interaction  of  light  with  tissue  have  been 
proposed  to  improve  the  detection  of  malignant  change.  These  include  spectroscopies  of 
various types, including autofluorescence (AF), elastic scattering, Raman, infrared absorption 
and diffuse reflectance [1–5]. To date, most of these techniques have been limited to point 
measurements, wherein only a small area of tissue is interrogated, e.g. via a fibre-optic contact 
probe, at any one time. This enables the acquisition of biochemical information but provides 
no spatial information about the tissue (i.e. images). Of the spectroscopic imaging techniques, 
one gaining interest for clinical application is narrow band imaging with reflected light (NBI) 
[6]. Its clinical utility is still being evaluated [7,8], however, and these instruments often 
include other contrast techniques such as autofluorescence, in order to obtain further contrast 
[9]. Autofluorescence provides label-free ‘molecular’ contrast that can be readily utilised for 
imaging,  allowing  the  rapid  and  relatively  non-invasive  collection  of  spatially-resolved 
information from areas of tissue up to tens of centimetres in diameter. 
In  general,  fluorescence  may  be  characterised  by  the  quantum  yield  of  the  emitting 
molecules (fluorophores), by their excitation and emission spectra, by the polarisation state of 
the  emission  and  by  the  fluorescence  decay  rate,  which  can  be  parameterised  by  the 
fluorescence ‘lifetime’, i.e. the average time taken to emit fluorescence after excitation from 
the  ground  energy  level  [10].  These  spectroscopic  properties  can  vary  between  different 
fluorophores and with a fluorophore’s local environment. For biological tissue, fluorescence-
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utilizing endogenous tissue fluorophores. In addition, the application of exogenous labels with 
specific fluorescence properties may be used in order to enhance image contrast. In general, a 
label-free approach is preferable for clinical imaging, particularly for diagnosis, as it avoids 
the  considerations  of  toxicity,  pharmacokinetics  and  regulatory  approval  associated  with 
exogenous agents. 
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Fig. 1. Equipment set-up for FLIM. The tissue sample is illuminated using a pulsed UV laser 
source carried via a fibre-optic cable to a diffuser. The emitted autofluorescence is imaged onto 
the GOI (which acts as a very fast shutter and an intensifier to amplify the weak fluorescence 
signal) and recorded by the CCD camera. Several time-gated images are recorded at different 
delays with respect to the excitation pulse. The resulting decay data is then analysed by fitting 
an exponential decay to the decay for each pixel in the field of view to generate a false-colour 
lifetime map of the image. 
The  principal  endogenous  tissue  fluorophores  include  collagen  and  elastin  crosslinks, 
reduced  nicotinamide  adenine  dinucleotide  (NADH),  oxidised  flavins  (FAD  and  FMN), 
lipofuscin, keratin and porphyrins. These fluorophores have excitation maxima in the near-
Ultraviolet  (UV)  or  blue/green  (325-500  nm)  spectral  regions.  The  corresponding 
fluorescence emission maxima occur at longer (Stokes-shifted) wavelengths in the near-UV to 
visible (390-700 nm) region of the spectrum [4]. The AF detected from biological tissue will 
depend on the concentration and quantum yield of the fluorophores present, on the presence of 
chromophores (principally hemoglobin) that absorb excitation and fluorescence light and on 
the degree of light scattering that occurs within the tissue [4]. AF signals therefore reflect the 
biochemical  and  structural  composition  of  the  tissue  and  so  are  altered  when  tissue 
composition is changed by disease states such as neoplasia. 
While clinical endoscopic AF intensity imaging is relatively simple to implement, e.g [11], 
with a number of systems becoming commercially available, the acquired images may be 
affected  to  an  unquantifiable  extent  by  variations  in  a  number  of  factors.  These  include 
fluorophore concentration, the temporal and spatial properties of the excitation flux, the angle 
of the excitation light, the detection efficiency, attenuation by light absorption and scattering 
within  the  tissue  and  spatial  variations  in  the  tissue  microenvironment  that  alter  local 
quenching of fluorescence. The use of two or more spectral emission windows can be used to 
improve quantitation through ratiometric imaging, but the heterogeneity in the distribution of 
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discrimination achievable. Although useful AF contrast is obtained in some cases, e.g [9,12], 
the above considerations have so far limited the widespread use of fluorescence imaging for 
the  detection  of  malignancy,  and  current  fluorescence  imaging  tools  in  clinical  use  are 
hampered by low specificity and a high rate of false positive findings [13–15]. 
Measurements of fluorescence decay profiles depend on relative (rather than absolute) 
intensity  values  and  fluorescence  lifetime  imaging  (FLIM),  for  which  the  fluorescence 
lifetime is determined for each pixel in a field of view [16], is therefore largely unaffected by 
many factors that limit steady-state intensity measurements [17]. Fluorescence lifetimes are, 
however,  affected  by  the  transfer  of  energy  from  a  fluorophore  to  its  surroundings  (non-
radiative decay) and so FLIM can map changes in local tissue microenvironment (e.g. pH, 
[O2], [Ca
2+]) [10]. 
The principal tissue fluorophores exhibit characteristic lifetimes ranging from hundreds to 
thousands  of  picoseconds  and,  while  changes  in  kinetics  of  time-resolved  fluorescence 
between normal versus malignant tissue were reported as early as 1986 [18], the complexity 
and performance of instrumentation associated with picosecond-resolved measurements, and 
particularly imaging, have hindered the development of FLIM as a clinical tool. Single point 
measurements  of  AF  lifetime  have,  however,  revealed  differences  between  normal  and 
neoplastic human tissue ex vivo in tumours of brain, breast and skin [19–21]. In addition 
similar differences have been described in vivo in the oral cavity, bladder, oesophagus and 
lung, and colon [17,22,23]. 
There have been a few reports of FLIM of AF in cancerous tissues. To date, most have 
concerned  the  application  of  laser  scanning  microscopes  and  particularly  multiphoton 
microscopes  that  inherently  incorporate  an  ultrafast  excitation  laser  and  for  which  the 
extension to FLIM is readily achieved using commercially available time-correlated single 
photon counting (TCSPC) electronics. Results obtained using multiphoton FLIM systems to 
study cancer include ex vivo studies of brain, skin, cervix, breast and in vivo studies in animals 
and human skin [24–29]. While laser scanning FLIM microscopy is a powerful approach for 
cell biology [30], its small field of view (typically less than 1 mm) makes it impractical for 
imaging the larger areas of tissue interrogation required for many clinical applications such as 
screening for disease, guided biopsy or intraoperative imaging. This issue, combined with the 
relatively high cost, is also likely to preclude laser scanning microscopes from many clinical 
point-of-care applications. 
We show here that time-gated FLIM, which may also be performed via an endoscope, can 
provide label-free contrast with cm-sized fields of view. There have been few applications of 
AF for imaging cancerous tissue since the first work implemented using a frequency domain 
FLIM system applied to ex vivo bladder and oral mucosa [31], although there has been one 
recent demonstration of endoscopic FLIM using a pulsed Nitrogen laser source on a hamster 
model of cancer [32]. Two key factors impeding clinical FLIM instrumentation have been the 
size, cost and complexity of the excitation lasers and the relatively low signal to noise ratio of 
the FLIM instrumentation. The recent availability of compact and convenient diode-pumped 
laser-based UV excitation sources has now addressed the first issue and for the second we 
have  developed  efficient  time-gated  FLIM  instrumentation  for  macroscopic  imaging, 
including through endoscopes [26,33]. 
Having previously shown that FLIM can distinguish areas of basal cell carcinoma from 
surrounding skin, we here present results from fresh tissue resections, illustrating, for the first 
time to our knowledge, the capability to image cancerous tissue in colon, liver and pancreas 
using FLIM of AF [34]. The apparatus is summarised in Fig. 1 and utilises a compact ultrafast 
laser excitation source at 355 nm and an optimised detection scheme using a gated optical 
intensifier read out using a cooled CCD camera. 
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2.1 Sample preparation 
Fresh surgical specimens from a number of organs (colon, stomach, bladder, liver, pancreas) 
were  collected  from  patients  undergoing  surgical  resection  for  malignant  disease.  FLIM 
imaging  preceded  fixation  with  formaldehyde.  The  specimens  were  either  opened  (colon, 
stomach,  bladder),  cut  open  (pancreas)  or  cut  into  serial  slices  (liver)  by  an  experienced 
histopathologist  to  reveal  the  malignancy.  The  specimens  were  then  washed  in  Hanks’ 
Balanced Salt Solution to remove blood, stool and other debris from the tissue surface, and 
imaged within 60 minutes of resection. After imaging, the biopsies were photographed and 
subsequently fixed in formaldehyde. Histological correlation with the photograph and FLIM 
image, and histopathological analysis was performed by an experienced histopathologist. This 
study was performed under a protocol approved by the Hammersmith and Queen Charlotte’s 
& Chelsea Hospitals Research Ethics Committee. All patients gave their informed consent to 
the use of tissue for medical research. 
2.2 Fluorescence Imaging Instrumentation and Protocol 
Experiments were carried out on a compact FLIM system designed and built by the Photonics 
Group at Imperial College London and installed in a laboratory space in the Histopathology 
Department to allow rapid ex vivo measurements of the resection specimens immediately after 
resection. The principles of operation and of the instrumentation used in time-domain FLIM 
have been described elsewhere [26,35]. In brief, a 10 ps pulsed frequency-tripled Nd:YVO4 
laser (Spectra-Physics Inc, Vanguard 350-HMD355) with an 80 MHz repetition rate provided 
pulsed UV excitation light at 355 nm. The laser output was delivered to the sample under 
investigation  by  a  1  m  length  of  optical  fibre  (Thorlabs,  FT-200-UMT)  and  a  divergent 
holographic  diffuser  (Physical  Optics  Corp,  60°  full  width  half  maximum).  The  emitted 
fluorescence was imaged via a 375 nm long-pass filter (Schott, GG375) onto a gated optical 
intensifier (GOI) (Kentech Instruments Ltd, HRI) coupled to a CCD camera (Hamamatsu, 
ORCA  ER)  (Fig.  1).  The  GOI  is  used  to  intensify  the  fluorescence  signal  and  produce 
ultrashort (1000 ps) time-gated ‘snapshots’ that are recorded by the CCD camera. By varying 
the delay between the excitation pulse and the opening of the gated intensifier, images of the 
exponentially decreasing fluorescence decay were recorded at 25 different time points at 250 
ps intervals. A typical decay acquisition took 4 seconds to record. For each sample, 5 decays 
were acquired sequentially and then averaged to minimise the impact of photobleaching on 
the lifetime measurement. The total FLIM acquisition time was ~20 s. The CCD camera was 
also used to record white light reflectance images of the sample under investigation. Image 
acquisition was controlled by a LabVIEW (National Instruments Corporation, Austin, Texas, 
USA) program developed in-house by members of the Photonics Group. 
2.3 Data processing, lifetime calculation and FLIM map generation 
For each pixel in the series of time-gated images, a lifetime value was computed using an 
iterative  weighted  non-linear  least-squares  (WNLLS)  algorithm  to  fit  a  mono-exponential 
decay curve to the data. The background signal due to CCD camera readout noise and offset 
was subtracted prior to fitting. False colour lifetime maps of the specimens were produced by 
assigning each pixel in the image a colour according to its lifetime value. The fluorescence 
intensity  threshold  was  adjusted  so  that  signals  from  outside  the  specimen  were  below 
threshold  and  excluded  from  lifetime  processing.  FLIM  maps  were  also  merged  with 
fluorescence  integrated  intensity  images  to  produce  images  displaying  both  lifetime  and 
intensity  information.  To  calculate  lifetime  values  from  different  regions  within  the  same 
image,  manually  delineated  region  of  interest  masks  were  drawn  from  the  white  light 
reflectance  images  and  applied  to  the  processing  of  the  fluorescence  decays.  All  data 
processing was performed with FLIMProcessing, a LabVIEW program written in-house by 
members of the Photonics Group. 
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The method for rapid lifetime determination FLIM has previously been described in detail, 
see  reference  [33]  and  references  therein.  In  brief,  a  low-jitter  electronic  delay  generator 
synchronised to the CCD camera’s frame grabber status signal was used to adjust the relative 
delay  between  time-gated  images  and  allowed  the  delay  to  be  altered  within  2.5  ms. 
Alternating frames, at delays of 0.2 and 5.7 ns  with respect to the excitation pulse, were 
acquired with an exposure time of 100 ms, resulting in a frame rate of ~7.7 Hz. The detection 
gate-width was set at 2.4 ns. 
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Fig.  2.  FLIM  of  a  fresh  hemicolectomy  specimen  containing  a  moderately  differentiated 
colonic  adenocarcinoma.  (a)  White  light  image  of  the  macroscopic  specimen  (area  of 
fluorescence  imaging  outlined).  Scale  bar  (white)  represents  2  cm.  (b)  H&E  stained 
histological  sections  of  the  tumour.  (c)  Fluorescence  integrated  intensity  image.  (d,  e) 
Intensity-weighted FLIM images. In (d) the lifetime is represented by a continuous spectrum 
colour scale while in (e) it is represented by a binary colour scale. (f) Lifetime distribution 
histograms calculated from the FLIM data. 
2.5 Statistical analysis 
We compared the mean lifetime and mean intensity values between the paired carcinoma and 
non-carcinoma regions for each sample with a Wilcoxon Signed-Rank test, as the data is 
nonparametric. The overlap of distributions of fluorescence intensity or fluorescence lifetime 
values  from  carcinoma  and  non-carcinoma  regions  for  each  sample  was  expressed 
quantitatively in terms of the area under the curve (AUC) of a receiver operating characteristic 
curve.  The  AUC  is  the  probability  that  the  fluorescence  intensity/lifetime  will  correctly 
identify a randomly selected ‘positive’ pixel (e.g. presence of cancer) compared to a randomly 
chosen ‘negative’ one (e.g. normal tissue). The possible values of AUC therefore run from 
0.5, indicating random assignment and therefore no diagnostic use, to either 0 or 1 (depending 
on the relative position of the histograms) for an ideal indicator. 
3. Results 
Figure  2  shows  fluorescence  intensity  and  FLIM  images  of  a  hemicolectomy  specimen 
containing a moderately differentiated colonic adenocarcinoma. The fluorescence lifetimes 
from the tumour (mean τ = 3730 ps) are longer than those from the normal mucosa (mean τ = 
3150 ps) and there is very little contrast between the two regions in the fluorescence intensity 
images, the FLIM and intensity (not shown) histograms have AUC values of 0.996 and 0.753 
respectively.  The  intensity-weighted  FLIM  map  combines  information  on  the  total 
fluorescence  intensity  and  the  fluorescence  lifetime  and  improves  the  visualization  of  the 
sample. Importantly, there is little overlap in the lifetime distributions from the areas of cancer 
and of the normal mucosa so a binary colour scale, rather than continuous, may be applied, 
with a cut-off chosen to distinguish between normal and cancerous tissue (in this case 3450 
ps). The binary scale would be useful if FLIM of AF was implemented as a clinical ‘red-flag’ 
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cancers  and  may  reflect  chemical  and  morphological  changes  occurring  with  malignant 
change in gastrointestinal mucosa (Fig. 3; mean τcancer = 2950 ps; mean τnormal = 2510 ps), with 
an AUC of 0.968. 
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Fig. 3. FLIM of a fresh partial gastrectomy specimen containing a moderately differentiated 
intestinal-type adenocarcinoma. (a) White light image of the macroscopic specimen (area of 
fluorescence imaging outlined). (b) Fluorescence integrated intensity image. Scale bar (white) 
represents 1 cm. (c) Intensity-weighted false-colour FLIM image (lifetime represented by a 
continuous spectrum colour scale). (d) Intensity-weighted false-colour FLIM image (lifetime 
represented by a discrete binary colour scale). (e) Lifetime histogram from the normal and 
cancerous regions of interest. 
Changes  in  AF  fluorescence  lifetime  are  not  restricted  to  glandular  mucosa  and  clear 
FLIM  contrast  is  seen  between  squamous  cell  carcinoma  of  the  bladder  and  surrounding 
transitional  mucosa  (Fig.  4).  The  contrast  is  similar  to  that  observed  in  an  earlier  study 
showing a decreased fluorescence lifetime in bladder exhibiting an erythematous urothelium 
[31]. The asymmetry of the histogram for the tumour ROI in Fig. 4(d) suggests that there may 
be two or more fluorescent subpopulations within this ROI, however, further work is required 
to  investigate  this.  In  this  specific  case  the  fluorescence  lifetime  discrimination  (AUC  = 
0.878) is not better than that obtained with intensity (AUC = 0.878). 
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Fig. 4. FLIM of a freshly resected bladder containing a moderately differentiated squamous cell 
carcinoma. (a) White light image of the macroscopic specimen (area of fluorescence imaging 
outlined). (b) Fluorescence integrated intensity image. Scale bar (white) represents 1 cm. (c) 
Intensity-weighted  false-colour  FLIM  image.  (d)  Histogram  showing  fluorescence  lifetime 
distributions from normal and cancerous regions of interest. 
To illustrate the clinical utility of the contrast provided by this FLIM instrument, a series 
of 18 colonic tumour resections were imaged, of which sixteen were shown by subsequent 
histopathological analysis to be invasive adenocarcinomas and two were serrated adenomas 
with focal high grade dysplasia. 
To quantify the contrast provided by each FLIM image, two regions of interest (ROI) were 
defined,  one  lesional  and  one  uninvolved  tissue.  A  mean  fluorescence  lifetime  was  then 
calculated from the fitted lifetime values for each of the pixels within the ROI. Figure 5(a) 
shows the difference in mean fluorescence intensity of the lesion compared to the surrounding 
tissue and 5(b) shows the corresponding difference in fluorescence lifetime. An AUC analysis 
on the pixel fluorescence intensity [Fig. 5(c)] and lifetime distributions [Fig. 5(d)] from each 
of the two ROI’s for each sample is also presented. 
Table 1. Summary of fluorescence data from the 16 imaged adenocarcinomas. Errors are 
the standard deviation of the values across the 16 specimens. p-values were calculated 
using a Wilcoxon sign-rank test 
n = 16  Fluorescence intensity (a.u.)  Fluorescence lifetime (ps) 
Normal  73,000 ± 15,000  3,200 ± 420 
Lesion  47,000 ± 12,000  3,700 ± 1,100 
Mean difference (lesion-normal)  −26,000 ± 20,000  570 ± 690 
p  0.0013  0.0008 
Relative change (lesion-normal)/normal  −0.36 ± 0.28  0.18 ± 0.22 
Mean AUC  0.20 ± 0.22  0.83 ± 0.22 
Interestingly,  the  two  specimens  of  serrated  adenoma  (17&18)  show  a  decrease  in 
fluorescence lifetime [Fig. 5(b)] compared to the surrounding tissue, contrary to the trend 
observed  for  the  cancers  (specimens  1-16).  These  two  non-malignant  samples  have  been 
excluded from the calculation of the average values from all of the carcinoma specimens in 
the analysis presented in Table 1. Further research is warranted to determine the extent to 
which this difference in lifetime for the serrated adenoma specimens is significant and to 
determine the cause. 
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trend of a longer fluorescence lifetime for tumours. For sample 13, a low AF intensity in the 
lesional  ROI  reduced  the  accuracy  of  the  measured  lifetime  difference.  For  sample  16, 
subsequent histopathology revealed that this specimen consisted of a small (2 mm) region of 
carcinoma inside a much larger region of adenoma. 
Table  1  contains  a  summary  from  the  fluorescence  data  acquired  from  the  16 
adenomcarcinomas.  The  quoted  errors  are  the  standard  deviation  of  the  values  across  all 
specimens. There is a statistically significant contrast between the lesion and normal tissue for 
both the fluorescence intensity (p = 0.0013) and the fluorescence lifetime images (p = 0.0008), 
with the general trend being that the lesions present a decrease in fluorescence intensity and 
an  increase  in  fluorescence  lifetime.  The  AUC  values  represent  the  probability  that  a 
randomly  chosen  pixel  in  a  cancerous  region  has  a  greater  fluorescence  lifetime  or 
fluorescence intensity than a randomly chosen pixel from a non-cancerous region. Therefore, 
on average, there is an 83% probability that any pixel from a lesion ROI will have a greater 
fluorescence lifetime and an 80% probability of a lower fluorescence intensity than any pixel 
from  normal  tissue.  It  is  important  to  note  that  quantitative  fluorescence  intensity 
measurements are difficult to perform due to variations in laser intensity, sample illumination, 
etc, while fluorescence lifetime measurements are not sensitive to these factors. In practice, 
total  intensity  values  can  also  be  obtained  from  fluorescence  lifetime  measurements  and 
therefore both intensity and lifetime data can be used to achieve contrast. 
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Fig. 5. (a) Graph showing difference in mean fluorescence intensity between the lesion ROI 
and normal tissue ROI for 18 colonic resections. (b) Plot of the mean difference in fluorescence 
lifetime between the lesion and normal ROIs. (c) AUC analysis of the fluorescence intensity 
data. (d) AUC analysis of the fluorescence lifetime data. Specimens 1-16 colonic tumours, 17-
18 serrated adenomas. 
4. Discussion 
In this study, fluorescence was excited at 355 nm, which can excite the majority of tissue 
fluorophores including collagen crosslinks, NADH, and (to a lesser extent) elastin, oxidised 
flavins, and porphyrins. In neoplastic change there are a number of factors that would be 
expected to alter the tissue AF and fluorescence lifetime. These include changes in: 
• The metabolic state of cancer cells (e.g. intracellular NADH and flavin concentrations, 
concentration and fluorescence lifetime of protein-bound NADH) [28,36–38]. 
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Type I collagen away from the tissue surface; tumour degradation of extracellular 
matrix or new matrix formation). 
• Tissue oxygenation and pH (altered fluorescence lifetime). 
• Tissue vascularity (increased light absorption by hemoglobin). 
• Nuclear:cytoplasmic ratio in cancer cells (altered light scattering within the tissue). 
Samples were imaged within 60 minutes of resection. Although the ex vivo AF of fresh 
biological tissue is similar to that derived from in vivo tissue, some physical and metabolic 
changes will affect AF [39]. Alterations may occur in the amounts of NADH present due to 
tissue  deoxygenation,  and  hemoglobin  content  may  also  change  ex  vivo,  altering  the 
absorption properties of the tissue. However, it is likely that any factors that change ex vivo 
tissue fluorescence would affect all areas of a sample to a similar degree and so would be 
unlikely to artefactually alter the lifetime contrast between normal and neoplastic tissue in ex 
vivo tissue. 
FLIM of AF is a potential new clinical imaging technique. UV light has very limited tissue 
penetration (measured to be typically <1 mm in skin, e.g [40].). Consequently UV light would 
be unable to excite fluorescence from within solid organs by external illumination. FLIM is 
therefore  limited  to  cancers  from  optically  accessible  tissue  surfaces  such  as  the  luminal 
surfaces of the gastrointestinal tract and bladder, and the skin, or during surgery where a non-
disturbed cancerous tissue surface is exposed. This paper presents a demonstration that the 
lifetime of neoplastic tissue AF induced by 355 nm UV excitation may be either shorter (e.g. 
bladder and pancreatic cancers) or longer (e.g. colonic and gastric adenocarcinoma) than AF 
from surrounding non-neoplastic tissue. Increased average AF lifetime values have previously 
been described in oral dysplastic lesions and gliomas by point measurements [17,19], whereas 
shorter  AF  lifetime  values  have  been  reported  in  colonic  adenomas  and  esophageal 
malignancies [23,41]. We note that the point probe AF lifetime  measurements of colonic 
adenoma employed a different excitation wavelength (337 nm) and detection band (530-570 
nm)  and  changes  in  fluorescence  lifetime  between  normal  and  malignant  tissue  have 
previously been shown to vary depending on emission wavelength [22,23]. Such findings are 
not surprising given the multiplicity of variables that can alter the lifetime of the AF emitted 
from  neoplastic  tissue  and  highlight  the  need  for  further  studies  to  identify  the  optimum 
fluorescence imaging parameters for contrasting a given disease and tissue type, including the 
optimization  of  the  excitation/emission  wavelength  and  possibly  the  extension  to 
instrumentation  employing  multiple  excitation  wavelengths  and/or  multiple  emission 
channels. 
For the ex vivo FLIM experiments reported here, we sampled each fluorescence decay 
profile with 25 time gates and fitted the data to an exponential decay model using an iterative 
WNLLS algorithm that typically took 10-20 seconds to compute. For maximal clinical utility 
and  ease  of  use,  however,  and  to  minimise  the  effects  of  movement  artefacts  (e.g.  from 
peristalsis), the acquisition and display of fluorescence lifetime images needs to be real-time. 
Practical real-time FLIM technology could greatly enhance the efficacy of a range of clinical 
modalities  including  laparoscopic  surgery,  gastrointestinal  endoscopy  (e.g.  Barrett’s 
esophagus surveillance, screening for early colonic or  gastric  neoplasia), colposcopy  (e.g. 
cervical screening), bronchoscopy and cystoscopy. 
To demonstrate this potential, we applied a rapid lifetime determination technique, using 
only two time-gated fluorescence images to produce each lifetime image [33]. FLIM images 
can thus be updated at up to 10 Hz, which is acceptable for most clinical situations. Figure 6 
shows a conventional FLIM image acquired over 20 s alongside a FLIM movie from a series 
of frames acquired at 7.7 Hz of the same tissue (Media 1). Although the rapidly acquired data 
exhibits more noise, the lifetime contrast between the cancerous and normal tissue is still 
apparent. In practice, the apparent noise is reduced when the images are viewed at 7.7 Hz as 
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Fig.  6.  FLIM  of  unfixed  pancreas  containing  an  area  of  pancreatic  cancer.  (a)  Standard 
acquisition (25 time gates; decay curve fitted to data using an iterative WNLLS algorithm; 
update rate ~0.1 Hz). Scale bar (white) represents 5 mm. (b) Rapid lifetime determination 
acquisition (Media 1) update rate 7.7 Hz. (c) Histogram of lifetime values from (A) showing 
lifetimes for the cancer and normal regions of interest. 
Further increases in FLIM imaging rates may be achieved using “single-shot” techniques 
utilising image splitting optics in combination with an optical delay line or segmented GOI, to 
realise simultaneous acquisition of up to four time-gated images [43,44]. In the longer term, 
the development of modulated CMOS technology may result in compact and cost-effective 
solid-state time-resolved detectors that could ultimately be miniaturised and deployed at the 
distal end of FLIM endoscopes, removing the need to transmit images through a fibre imaging 
bundle [45]. 
The  measurement  of  fluorescence  lifetimes  in  biological  tissue  is  complicated  by  the 
presence of multiple fluorophores that exist in a range of different microenvironments [10]. 
As a result, the fluorescence decays are generally complex. Although they do not fit precisely 
to a single exponential decay profile, in practice they can be approximated to this model, 
returning  an  average  fluorescence  lifetime.  This  has  been  used  previously  for  FLIM  of 
biological tissue AF and been shown to generate lifetime contrast between different types and 
states  of  tissue  [26,34,46]  and  allows  the  rapid  acquisition/processing  necessary  for  a 
clinically useful imaging tool. 
More complex decay models, for example double or triple exponentials, would provide 
better fits and have been used when analysing lifetime data of biological tissue AF. This 
improved fit, however, is often only the result of the higher number of fitting parameters used; 
it is no more realistic to assume the presence of only 2 or 3 mono-exponentially decaying 
fluorophores (or a single fluorophore with 2 or 3 discrete decay constants) in each pixel of the 
entire FLIM map than it is to assume the presence of a single fluorophore [47]. Fitting multi-
exponential  decays  is  more  vulnerable  to  noise  artefacts  and  requires  significantly  longer 
acquisition and computation time compared with fitting a single exponential decay curve to 
the data. 
Despite the lifetime values generated in our FLIM maps being an approximation to the 
complex nature of the fluorescence decay and the absolute lifetime values, clear meaningful 
contrast between normal tissue and neoplasia is still obtained and the potential for FLIM 
endoscopy is clear. However, if the AF signal is sufficiently strong so as to allow complex 
exponential fitting, then it clearly provides additional opportunities to contrast different types 
and states of tissue. This is demonstrated in Fig. 7, which shows a 10 mm thick slice through a 
right trisegmentectomy liver resection containing a large metastatic adenocarcinoma from a 
colonic primary. A margin of paler tissue representing radiofrequency ablation (RFA) thermal 
injury can be seen along the bottom edge of the specimen in the white light image. 
Although the fluorescence signal from the area of RFA injury and normal liver can be 
distinguished on the basis of the single exponential fit [Fig. 7(c)], it is not possible to contrast 
normal and tumour tissue in this case. Interestingly, all three regions are clearly contrasted 
when  performing  a  stretched  exponential  fit  [Fig.  7(d)–7(f)]  [48].  Both  the  stretched 
exponential fluorescence lifetime and heterogeneity fit parameter (a measure of the lifetime 
distribution in a pixel) provide contrast between all three regions. This data highlights the 
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Fig. 7. FLIM of an unfixed liver containing metastatic colorectal carcinoma and an area of 
radiofrequency ablation damage. (a) White light image of the specimen (area of fluorescence 
imaging indicated by rectangle). Scale bar (white) represents 2 cm. (b) Fluorescence intensity 
image. (c) FLIM map obtained with a single exponential fit. (d) Stretched exponential FLIM 
map  and  (e)  heterogeneity  images  obtained  with  a  stretched  exponential  fit.  (f)  Lifetime 
histogram  generated  from  the  stretched  exponential  fit  demonstrating  contrast  between  the 
three areas of the sample. 
5. Conclusion 
The use of FLIM of tissue AF to aid the detection and delineation of neoplastic change is an 
emerging concept. To date, the complexity of imaging picosecond-resolved time-gated AF has 
precluded the clinical exploitation of this valuable source of tissue contrast. To our knowledge 
this is the first study of FLIM applied to mucosal carcinomas and the first report of practical 
FLIM instrumentation that uses robust all-solid state laser technology. In addition, we have 
demonstrated  the  potential  of  FLIM  for  extended  wide-field  imaging  providing  cm-sized 
fields of view of liver, gastric, bladder and pancreatic cancer. 
We  believe  that  FLIM  has  significant  potential  clinical  value  as  a  label-free  imaging 
modality to quickly screen tissue and detect small cancers and pre-cancerous lesions that are 
not immediately apparent to the naked eye. The wide-field nature of this imaging modality 
allows the comparative display of healthy tissue surrounding ‘abnormal’ tissue, and hence its 
role is envisaged as a ‘red flag’ guide to potential areas of malignancy, reducing time and the 
number of screening biopsies taken. In addition, FLIM could be a tool for delineating areas of 
malignancy  and  enhancing  the  identification  of  tumour  margins.  This  would  be  useful 
preoperatively  in  judging  the  required  extent  of  surgical  resections  or  the  application  of 
ablative therapies. 
Further studies will be necessary to optimise and refine the technique to maximise the 
contrast available for a given tissue or tumour and these promising early findings should be 
replicated in vivo. Future work will also include an investigation of FLIM contrast in earlier 
disease states, e.g. precancerous tissue, and in more subtle disease states, e.g. flat dysplasia, 
than was possible with the surgical resection specimens that were available for this study. 
However, it is already apparent that lifetime imaging adds a useful additional dimension of 
contrast  to  fluorescence  instrumentation  and  that  the  clinical  application  of  FLIM  for  the 
detection and delineation of malignancy is now feasible and informative. 
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